Rhode Island Medicaid (Tufts Health RITogether) no longer covers GLP-1s prescribed only for weight loss as of October 1, 2026. Wegovy and Zepbound stay covered for cardiovascular risk reduction, MASH with advanced fibrosis and moderate-to-severe sleep apnea; diabetes GLP-1s are unaffected.
By Dr. SkinnyVIP · Published October 19, 2026 · Quotes link to the original policy or report
“Effective October 1, 2026, Tufts Health RITogether (Rhode Island Medicaid) will no longer cover GLP-1 medications when prescribed solely for weight loss, including Saxenda, Wegovy, Zepbound, and Foundayo.”
“All existing prior authorizations for weight-loss use will be end-dated by September 30, 2026, and affected members will be notified.”
Rhode Island joins a trend Stateline documented in April: Medicaid programs in California, New Hampshire, Pennsylvania and South Carolina had already eliminated coverage of the drugs for weight loss, and Massachusetts followed in July.
“Wegovy and Zepbound remain covered for specific FDA-approved indications (cardiovascular risk reduction, MASH with advanced fibrosis, and moderate-to-severe sleep apnea). GLP-1s approved for type 2 diabetes treatment will continue to be covered.”
If you have one of those diagnoses, your prescriber can request authorization under that indication rather than weight loss. That is the first thing to ask about.
1. Ask your plan one question in writing. “Is there a continuation-of-therapy or medical-necessity exception for members already on a GLP-1, and what documentation does it need?” Many policies keep an exception for diabetes, cardiovascular risk reduction, sleep apnea or liver disease; a letter from your prescriber may qualify you.
2. Check the two public cash-pay routes for the brand-name drug. LillyDirect sells Zepbound to self-pay patients at published prices by dose ($299 to $699 a month for vials as of October 2026, per our Real-Price Index). If you are on Medicare Part D, the Medicare GLP-1 Bridge offers Wegovy or Zepbound for a $50 copay through December 2027 if you meet its criteria (details).
3. If neither fits, know the compounded option's real number. SkinnyVIP's clinician-prescribed compounded tirzepatide is $695 for a 3-month plan (about $232 a month) or $350 for a single month, the same price at every dose, with no membership, no subscription and no automatic renewal; you pay once per plan and nothing bills again unless you ask. If a licensed clinician does not prescribe, the medication cost is refunded in full. Compounded medications are not FDA-approved products; read how it works and what that means before deciding.
Not for weight loss alone, as of October 1, 2026. Per the Tufts Health RITogether notice, Zepbound and Wegovy remain covered for cardiovascular risk reduction, MASH with advanced fibrosis and moderate-to-severe obstructive sleep apnea, and GLP-1s for type 2 diabetes are unaffected.
The notice states that existing prior authorizations for weight-loss use were end-dated by September 30, 2026, and that affected members would be notified. Ask your prescriber whether you qualify under a covered indication instead.
At SkinnyVIP, $695 for a 3-month plan (about $232 a month) or $350 for a single month, the same price at every dose, with no membership or automatic renewal. Compounded medications are not FDA-approved products; a licensed clinician decides whether to prescribe, and prescription is not guaranteed.
LillyDirect sells Zepbound to self-pay patients at published prices by dose, and Medicare Part D members may qualify for the $50 Medicare GLP-1 Bridge through December 2027. Rhode Island Medicaid members are generally not Part D members unless dually eligible.
Ask your plan about exceptions, check the brand-name cash routes, then compare. SkinnyVIP: $695 for 3 months (about $232/month) or $350 for one, any dose, nothing renews.
Start your consultationCompounded tirzepatide is prepared by licensed compounding pharmacies under physician supervision. Compounded medications are not FDA-approved products, and FDA does not review compounded drugs for safety, effectiveness, or quality before marketing. Compounded tirzepatide is separate from FDA-approved Mounjaro® and Zepbound®. A licensed clinician reviews every request; prescription is not guaranteed. Individual results vary. Not affiliated with Novo Nordisk (Ozempic®/Wegovy®) or Eli Lilly (Mounjaro®/Zepbound®). This page is general information about published coverage policies, not insurance, legal or medical advice; confirm details with your plan.